may 26, 2016 - FDA announced required safety labeling changes
for methadone and buprenorphine products
when used by pregnant women for medication-
assisted treatment (MAT) of opioid use disorder
to ensure providers have complete information
about the benefits and risks of these products.
FDA approved Probuphine, the first
buprenorphine implant for the maintenance
treatment of opioid dependence.
Added to timeline:
Opioids and the FDA
Date:
